Skip to content

Ruminant Trans Fats and the Risk of Cardiovascular Disease in Women

Ruminant Trans Fats and the Risk of Cardiovascular Disease in Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00930137
Acronym
TRANSW
Enrollment
64
Registered
2009-06-30
Start date
2009-09-30
Completion date
2011-09-30
Last updated
2013-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

Cardiovascular disease, Trans fatty acids, Ruminant, Blood lipids, Lipoproteins, Women

Brief summary

While the deleterious effects of trans fat from industrial sources (iTFA) on cardiovascular health are well established, the impact of TFA from ruminants (rTFA) on cardiovascular risk factors has not been as well characterized. We have previously shown in men that a very high dietary intakes of rTFA (\>3.5% of energy) leads to unfavourable changes in lipid cardiovascular risk factors that are similar to those seen with iTFA. However, our data also indicated that achievable intakes of rTFA that remain well above the current human consumption (1.5% of energy intake) had neutral effects on plasma lipids and other cardiovascular disease (CVD) risk factors in men. Other studies have also suggested that the LDL and HDL response to very high dietary intakes of rTFA (\>5% of energy) in women may be different than in men. The general objective of the study is to investigate for the first time in a double-blind randomized controlled study the impact of high but yet achievable intake of ruminant trans fatty acids on plasma LDL-Cholesterol and other risk factors for CVD in healthy women.

Detailed description

Ruminant trans fatty acids (rTFA) will come from an experimental butter formulated from dairy fat obtained after having modified the regimen of lactating cows. All diets will be identical in terms of menus, calories and macronutrient composition with the exception of TFA levels. All foods will be provided to study participants. Based on a 2500 kcal/day regimen, an intake of 4.1g of rTFA will represent 37 kcal/day (1.5% of energy intake) while the intake of 0.7 g of rTFA in the control diet will represent 6 calories (0.3% of energy). The 2 experimental diets will be formulated so that the percentage of daily calories from fat (33%), carbohydrates (52%) and proteins (15%) will meet the dietary recommendations of the American Heart Association and the NCEP for primary prevention of CVD.

Interventions

OTHERisocaloric for week diet

Consumption of the 2 experimental diets 1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal); 2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal).

Sponsors

Institute of Nutraceuticals and Functional Foods
CollaboratorOTHER
Dairy Farmers of Canada
CollaboratorOTHER
Dairy Australia
CollaboratorINDUSTRY
Laval University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy women using or not contraceptive agents or hormone supplementation * For pre-menopausal women: regular menstrual cycle for the last 3 months (25- 35 days) * LDL-Cholesterol concentration between 2.5 and 4.0 mmol/L * Stable body weight (+/- 2 kg) for 6 months before the beginning of the study * Smoking or not

Exclusion criteria

* Previous history of cardiovascular disease, type 2 diabetes and monogenic dyslipidemia * Subjects taking medications for hyperlipidemia or hypertension * Endocrine disorders * Body mass index \> 35 kg/m2 * Food allergies * Women with extreme nutritional habits such as vegetarism or alcohol consumption \> 2 drinks/day * Elite athletes

Design outcomes

Primary

MeasureTime frame
Plasma LDL-Cholesterol concentrationsAt the beginning of the study and the end of the 2 for-week diets

Secondary

MeasureTime frame
Blood lipids and apolipoproteins (Total cholesterol, HDL-Cholesterol, Triglycerides, Apo A1, Apo B)At the beginning of the study and the end of the 2 for-week diets
CRPAt the beginning of the study and the end of the 2 for-week diets
Blood pressureAt the beginning of the study and the end of the 2 for-week diets
Anthropometric measures (waist and hip circumferences)At the beginning of the study and the end of the 2 for-week diets

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 27, 2026